Literature DB >> 17095762

Osteonecrosis of the jaw after treatment with bisphosphonates: is irreversible, so the focus must be on prevention.

Basile Nicolas Landis, Michel Richter, Ivan Dojcinovic, Max Hugentobler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17095762      PMCID： PMC1635618          DOI： 10.1136/bmj.39024.647558.BE

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  8 in total

Review 1.  Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.

Authors:  W M Drake; D L Kendler; J P Brown
Journal:  Clin Ther       Date:  2001-04       Impact factor: 3.393

2.  Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment.

Authors:  Robert E Marx; Yoh Sawatari; Michel Fortin; Vishtasb Broumand
Journal:  J Oral Maxillofac Surg       Date:  2005-11       Impact factor: 1.895

3.  Pharmacokinetics of alendronate: an overview.

Authors:  J H Lin; G Russell; B Gertz
Journal:  Int J Clin Pract Suppl       Date:  1999-04

Review 4.  Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws.

Authors:  Sook-Bin Woo; John W Hellstein; John R Kalmar
Journal:  Ann Intern Med       Date:  2006-05-16       Impact factor: 25.391

Review 5.  Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates.

Authors:  Matthew C Farrugia; Don-John Summerlin; Edward Krowiak; Tod Huntley; Stephen Freeman; Richard Borrowdale; Charles Tomich
Journal:  Laryngoscope       Date:  2006-01       Impact factor: 3.325

6.  Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic.

Authors:  Robert E Marx
Journal:  J Oral Maxillofac Surg       Date:  2003-09       Impact factor: 1.895

7.  Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.

Authors:  Salvatore L Ruggiero; Bhoomi Mehrotra; Tracey J Rosenberg; Stephen L Engroff
Journal:  J Oral Maxillofac Surg       Date:  2004-05       Impact factor: 1.895

8.  Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid.

Authors:  Jeanette Wood; Karine Bonjean; Stephan Ruetz; Akeila Bellahcène; Laetitia Devy; Jean Michel Foidart; Vincent Castronovo; Jonathan R Green
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030
  8 in total
  5 in total

1.  Osteonecrosis of the jaw and bisphosphonates: historical lesson from occupational medicine.

Authors:  Eugene R Waclawski
Journal:  BMJ       Date:  2006-11-25

2.  Osteonecrosis of the jaw and bisphosphonates: editorial was confusing.

Authors:  Mark J Bolland; Andrew Grey; Ian R Reid
Journal:  BMJ       Date:  2006-11-25

3.  Osteoinductivity of demineralized bone matrix is independent of donor bisphosphonate use.

Authors:  Zvi Schwartz; Sharon L Hyzy; Mark A Moore; Shawn A Hunter; Chad J Ronholdt; MoonHae Sunwoo; Barbara D Boyan
Journal:  J Bone Joint Surg Am       Date:  2011-12-21       Impact factor: 5.284

4.  A case of variegate porphyria in association with coeliac disease and bisphosphonate associated dental osteonecrosis.

Authors:  Olayinka A Ogundipe
Journal:  J Clin Med Res       Date:  2009-12-28

5.  Reveromycin A Administration Prevents Alveolar Bone Loss in Osteoprotegerin Knockout Mice with Periodontal Disease.

Authors:  Manami Mizuno; Ken Miyazawa; Masako Tabuchi; Miyuki Tanaka; Mamoru Yoshizako; Chisato Minamoto; Yasuyoshi Torii; Yusuke Tamaoka; Makoto Kawatani; Hiroyuki Osada; Hatsuhiko Maeda; Shigemi Goto
Journal:  Sci Rep       Date:  2015-11-12       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.